Search results
Results From The WOW.Com Content Network
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Amphetamine, an NDRA and one of the most well-known DRAs. 4-Methylaminorex (4-MAR), the cis- isomer being one of the most dopamine-selective NDRAs known.. A dopamine releasing agent (DRA) is a type of drug which induces the release of dopamine in the body and/or brain.
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
Drugs of abuse increase the VTA's ability to project dopamine to the rest of the reward circuit. [6] These structural changes only last 7–10 days, [7] however, indicating that the VTA cannot be the only part of the brain that is affected by drug use, and changed during the development of addiction.
Conversely, these levels are decreased and the rewarding properties of BSR are blocked following administration of drugs that antagonize dopamine receptors or reduce the amount of extracellular dopamine, by promoting either degradation or re-uptake of the neurotransmitter. While dopamine is generally considered to be the main neurotransmitter ...
The most common drugs of abuse stimulate the release of dopamine, which creates both their rewarding and the psychomotor effects. Compulsive drug-taking behaviors are a result of the long-lasting or permanent [30] [31] functional changes in the mesolimbic dopamine system arising from repetitive dopamine stimulation. Molecular and cellular ...
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
The anticipation of most types of rewards increases the level of dopamine in the brain, [4] and many addictive drugs increase dopamine release or block its reuptake into neurons following release. [5] Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones.